Literature DB >> 20957676

Interpreting borderline BeLPT results.

D C Middleton1, A S Mayer, M D Lewin, M M Mroz, L A Maier.   

Abstract

BACKGROUND: The beryllium lymphocyte proliferation test (BeLPT) identifies persons sensitized to beryllium (BeS) and thus at risk for chronic beryllium disease (CBD). BeLPT test results are abnormal (AB), borderline (BL), or normal (NL). This manuscript addresses the predictive value and interpretation of BL BeLPT results.
METHODS: The various three-result combinations that meet or exceed a nominal referral criteria of 1 AB + 1 BL are assessed with probability modeling and compared.
RESULTS: At 2% prevalence, the three-result combinations that meet or exceed this referral criteria and associated probabilities of BeS are: (a) 1 AB + 1 BL + 1 NL (72%); (b) 3 BL (91%); (c) 2 AB + 1 NL (95%); (d) 1 AB + 2 BL (99%); (e) 2 AB + 1 BL (100%); and (f) 3 AB (100%).
CONCLUSION: These results suggest that BL results are meaningful and that three BL results predict BeS across a broad range of population prevalences. An analysis of longitudinal BeLPT results and clinical findings from an actual surveillance program is warranted to confirm the model's predictions.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20957676      PMCID: PMC4347846          DOI: 10.1002/ajim.20909

Source DB:  PubMed          Journal:  Am J Ind Med        ISSN: 0271-3586            Impact factor:   2.214


  12 in total

1.  Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): preliminary analysis of the ongoing workforce survey.

Authors:  D C Deubner; M Goodman; J Iannuzzi
Journal:  Appl Occup Environ Hyg       Date:  2001-05

2.  Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease.

Authors:  M M Mroz; K Kreiss; D C Lezotte; P A Campbell; L S Newman
Journal:  J Allergy Clin Immunol       Date:  1991-07       Impact factor: 10.793

3.  The BeLPT: algorithms and implications.

Authors:  D C Middleton; M D Lewin; P J Kowalski; S S Cox; D Kleinbaum
Journal:  Am J Ind Med       Date:  2006-01       Impact factor: 2.214

4.  Beryllium health effects in the era of the beryllium lymphocyte proliferation test.

Authors:  L A Maier
Journal:  Appl Occup Environ Hyg       Date:  2001-05

5.  The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance.

Authors:  Arthur W Stange; F Joseph Furman; Duane E Hilmas
Journal:  Am J Ind Med       Date:  2004-11       Impact factor: 2.214

Review 6.  Beryllium: a modern industrial hazard.

Authors:  Kathleen Kreiss; Gregory A Day; Christine R Schuler
Journal:  Annu Rev Public Health       Date:  2007       Impact factor: 21.981

7.  Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant.

Authors:  L S Newman; M M Mroz; L A Maier; E M Daniloff; R Balkissoon
Journal:  J Occup Environ Med       Date:  2001-03       Impact factor: 2.162

8.  Epidemiology of beryllium sensitization and disease in nuclear workers.

Authors:  K Kreiss; M M Mroz; B Zhen; J W Martyny; L S Newman
Journal:  Am Rev Respir Dis       Date:  1993-10

9.  Optimizing BeLPT criteria for beryllium sensitization.

Authors:  D C Middleton; J Fink; P J Kowalski; M D Lewin; T Sinks
Journal:  Am J Ind Med       Date:  2008-03       Impact factor: 2.214

10.  Rocky Flats Beryllium Health Surveillance.

Authors:  A W Stange; F J Furman; D E Hilmas
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

View more
  2 in total

Review 1.  The role of lymphocyte proliferation tests in assessing occupational sensitization and disease.

Authors:  Stella E Hines; Karin Pacheco; Lisa A Maier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

2.  Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.

Authors:  Lori J Silveira; Erin C McCanlies; Tasha E Fingerlin; Michael V Van Dyke; Margaret M Mroz; Matthew Strand; Andrew P Fontenot; Natalie Bowerman; Dana M Dabelea; Christine R Schuler; Ainsley Weston; Lisa A Maier
Journal:  J Immunol       Date:  2012-09-12       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.